Skip to content
Screener

GeneDx Holdings WGS Diagnostic Test — Total Revenue

Similar metrics at other companies

Idexx Laboratories logo
IDXXTotal CAG Diagnostics recurring revenue — Total Revenue
$1.14B+14.3%
Idexx Laboratories logo
IDXXCAG Diagnostics recurring revenue: — Total Revenue
$974.71M+11.0%
Idexx Laboratories logo
IDXXCAG Diagnostics capital - instruments — Total Revenue
$47.17M-19.5%
TMH
TMHCWest — Total Revenue
$572.07M-21.4%
Andersen Group logo
ANDGWest — Total Revenue
$99.89M+11.3%
Beazer Homes USA, Inc. logo
BZHWest — Total Revenue
$287.32M-12.7%

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$2.08B-27.6%
Enterprise value$2.08B-27.0%
P/S4.7×-3.2×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%—
Net margin-17.6%—
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%—
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001818331-26-000041
Line itemThree months ended March 31, 20262025
Revenue
Diagnostic test revenue$101,299$85,759
Other revenue9551,356
Total revenue102,25487,115
Cost of services34,04328,639
Gross profit68,21158,476
Research and development19,80412,577
Selling, general and administrative74,59150,450

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is GeneDx Holdings's diagnostic test — total revenue?
GeneDx Holdings (WGS) reported diagnostic test — total revenue of $101.3M in Q1 2026.
How has GeneDx Holdings's diagnostic test — total revenue changed year-over-year?
GeneDx Holdings's diagnostic test — total revenue increased by 18.1% year-over-year, from $85.76M to $101.3M.
What is the long-term trend for GeneDx Holdings's diagnostic test — total revenue?
Over 4 years (2021 to 2025), GeneDx Holdings's diagnostic test — total revenue has grown at a 19.4% compound annual growth rate (CAGR), from $205.1M to $416.39M.
What does diagnostic test — total revenue mean?
This metric represents the total gross revenue generated from the sale and delivery of diagnostic testing services within a specific business segment. It reflects the market demand and commercial adoption of the company's diagnostic portfolio. Monitoring this figure helps investors assess the top-line growth trajectory and competitive positioning of the segment's core offerings.

Ask your AI about GeneDx Holdings's diagnostic test — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude